Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going-Reference-Cited by-同舟云学术

Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going

Published:2024-06 Issue: Volume:127 Page:102748
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Muniz Miguel,Loprinzi Charles L,Orme Jacob J,Koch Regina M,Mahmoud Ahmed M,Kase Adam M,Riaz Irbaz B,Andrews Jack R,Thorpe Matthew P,Johnson Geoffrey B,Kendi Ayse T,Kwon Eugene D,Nauseef Jones T,Morgans Alicia K,Sartor Oliver,Childs Daniel S

Funder

Mayo Clinic

National Institutes of Health

National Center for Advancing Translational Sciences

Publisher

Elsevier BV

Reference116 articles.

1. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer;Sartor;N Engl J Med,2021

2. Exposure-adjusted safety analyses of the VISION phase 3 trial of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer, American Society of;Chi;Clin Oncol,2022

3. [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial;Hofman;Lancet,2021

4. LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore);Sartor;Ann Oncol,2023

5. Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA;Feuerecker;Eur Urol,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intra-arterial administration of PSMA-targeted radiopharmaceuticals for brain tumors: is the era of interventional theranostics next?;Expert Review of Anticancer Therapy;2024-08-29